FDA Advisory Committee does not recommend that sotagliflozin receive approval for glucose lowering in adults with type 1 diabetes (T1D) and Chronic Kidney Disease (CKD)
Update – November 22, 2024 This morning, Lexicon Pharmaceuticals, Inc. (Lexicon) announced they received a “deficiencies preclude discussion” letter from…
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
A Complication of Type 1: Gastroparesis
Gastroparesis is a condition when the stomach is unable to empty itself properly, leading to problems such as becoming full…
Breakthrough T1D Staff Share Personal Stories About Diabetic Eye Disease
Breakthrough T1D staff share their experiences with diabetic eye disease to help raise awareness of the importance of being proactive…
Interview: I’ve Got Hope Back in my Life
The Mary Tyler Moore Vision Initiative has a lofty goal: To halt and reverse vision loss from diabetes. Here’s one…
Moonshot Reimagined: Our Vision to Halt and Reverse Vision Loss
Breakthrough T1D has taken a bold new step to prevent and restore vision loss and blindness: Restoring Vision Moonshot, in…
100, 100: Ending Diabetic Eye Disease, Forever
Breakthrough T1D has supported eye disease research since its beginning, and has driven discoveries that have reduced the risk of…
Two Studies Shed Light on Diabetic Kidney Disease
Two recent publications shed light on which people with type 1 diabetes will develop end-stage kidney disease, a complication of…
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him…
At 37, I’m Fighting to Save my Eyesight
At the age of 37, I’m fighting to save my eyesight, a complication of type 1. People are also at…
